Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)
Candel Therapeutics (CADL) posted Preferred Stock Liabilities of $22.5 million for Q2 2021, little changed sequentially from $22.5 million in Q1 2021, and down 15.29% YoY from $26.6 million in Q2 2020.
Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Candel Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $22.5 million in Q2 2021.
- Quarterly Preferred Stock Liabilities fell 15.29% year-over-year to $22.5 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $22.5 million (down 15.29% YoY) and the FY2020 annual result came in at $22.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $22.5 million in Q2 2021 per CADL's latest filing, from $22.5 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $26.6 million in Q2 2020 and troughed at $22.5 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 22.50 Mn |
| Mar 31, 2021 | 22.50 Mn |
| Dec 31, 2020 | 22.50 Mn |
| Sep 30, 2020 | 26.56 Mn |
| Jun 30, 2020 | 26.56 Mn |